



PRESS RELEASE

Genelux Appoints George Vandeman and Thomas Zindrick to Board of Directors

Vandeman becomes Vice Chairman and fifth independent Director on nine-member Board

SAN DIEGO, May 28, 2014 – Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced the appointment of Mr. George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux Corporation, to the company's Board of Directors. Mr. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corporation Board to nine members.

"I am honored to welcome Mr. Vandeman to the Genelux Board as our Vice Chairman," said James L. Tyree, Chairman of Genelux. "George brings invaluable professional experience in corporate development, product licensing, corporate transactions, corporate governance and strategic planning to the Genelux Board."

Mr. Vandeman retired in 2000 after five years at Amgen as Senior Vice President, General Counsel and Chairman of the Company's Operating Committee. During his tenure at Amgen, he was responsible for the Corporate Development and Product Licensing groups, the company's legal department, as well as mergers and acquisitions and product licensing activities.

Immediately prior to joining Amgen, Mr. Vandeman was a senior partner and head of Mergers & Acquisitions for the international law firm of Latham & Watkins, where he worked for nearly three decades representing bidders, targets and financial advisors in corporate control transactions and advising Boards of Directors as to M&A and corporate governance matters. Since his retirement from Amgen, he has been a principal in Vandeman & Co., a private investment firm.

Thomas Zindrick, also named to the Board of Directors, was recently appointed CEO and president of Genelux Corporation, succeeding founder and former CEO and President, Aladar A. Szalay, Ph.D. Prior to Genelux, Mr. Zindrick was CEO of Amitech Therapeutic Solutions, Inc., a La Jolla, California based discovery and drug development company, and has also served as an independent consultant to Genelux Corporation on a number of legal and business-related matters. Zindrick retired from Amgen in 2009 after a distinguished 16 year career, where he served as Vice President, Associate General Counsel, leading intellectual property, licensing and regulatory law teams that were instrumental in achieving acquisitions totaling over twenty billion dollars and the licensing and development of six therapeutic products and numerous clinical candidates. Mr. Zindrick also served as Chief Compliance Officer, reporting to the Board of Directors.

About Genelux Corporation

Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNA into cancer cells without harming healthy cells. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company's lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple Phase 1 and 1/2 clinical trials in the US and Europe. For more information please visit <http://www.genelux.com>.

Contact:

Richard Roose
RCI Partners
415-202-4445



rick.roose@rci-partners.com